Overview - The report provides a comprehensive analysis of the synthetic biology industry in China, covering its development status, market trends, and competitive landscape from 2025 to 2031 [1][3]. Industry Definition and Structure - Synthetic biology is defined and categorized, with a detailed breakdown of the industry chain structure and ecosystem [3][4]. - The report includes a regional heat map illustrating the distribution of synthetic biology activities across different areas [3]. Global Development and Trends - The global synthetic biology industry has experienced significant growth, with a focus on policy and technology analysis, including patent applications and key players [4][5]. - Market size and structure are analyzed, highlighting the growth potential in various segments [4][5]. Chinese Market Analysis - The report details the current state of the synthetic biology industry in China, including its historical development and unique characteristics [5][6]. - It discusses the commercial models prevalent in the industry and identifies representative companies [5][6]. Investment and Financing - An analysis of investment trends in the synthetic biology sector reveals significant funding activities and the distribution of investment across different fields [6][7]. - The report summarizes key financing events and the overall investment landscape [6][7]. Competitive Landscape - The competitive dynamics of the synthetic biology industry in China are examined, including the types and numbers of competitors [7][8]. - The report assesses the competitive positioning of leading companies and their strategies for global expansion [7][8]. Technological Development - The report highlights the current state of technology standards in synthetic biology, including ongoing research and development efforts [8][9]. - Key technologies such as gene sequencing and editing are analyzed for their impact on the industry [8][9]. Future Outlook - The report predicts future growth points for the synthetic biology industry, driven by downstream application markets and supportive national policies [9][10]. - It outlines potential investment opportunities and strategic recommendations for stakeholders in the industry [10][11].

Investment Rating - The industry investment rating is "Overweight" [1] Core Views - The chemical sector has shown a performance increase of 4.03% in the week from July 21 to July 25, 2025, ranking 8th among all sectors, outperforming the Shanghai Composite Index by 2.35 percentage points [4][22] - The report highlights a continued trend of differentiation in the chemical industry for 2025, recommending focus on sectors such as synthetic biology, pesticides, chromatography media, sugar substitutes, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [4] Summary by Sections 1. Industry Review - The chemical sector's overall performance for the week was a 4.03% increase, ranking 8th among sectors, with the Shanghai Composite Index increasing by 1.67% and the ChiNext Index by 2.76% [22] - The top three performing sub-sectors were construction materials (8.20%), coal (7.98%), and steel (7.67%) [22] 2. Key Industry Dynamics - The report discusses the upcoming implementation of quota policies for third-generation refrigerants, which are expected to enter a high prosperity cycle due to supply constraints and stable demand growth from markets like heat pumps and cold chains [5] - The electronic specialty gases market is highlighted as a critical area for domestic substitution opportunities, driven by rapid upgrades in the semiconductor industry and increasing demand for high-end electronic specialty gases [6][8] - The light hydrocarbon chemical trend is noted as a global shift, with a move towards lighter raw materials for olefin production, which is expected to enhance the valuation of leading companies in this sector [8] - The COC polymer industry is experiencing accelerated domestic industrialization, with significant potential for domestic companies to break through supply bottlenecks [9] - The potassium fertilizer market is anticipated to rebound as major producers reduce output, leading to a tightening supply situation and increased prices [10] - The MDI market is characterized by oligopoly, with a favorable supply structure expected as demand recovers, making it a resilient chemical product through economic cycles [12]

Core Insights - National strategic investment platform Guotou Juli has completed a strategic investment of 450 million yuan in leading synthetic biology company Yikole Biotechnology [1] - Yikole's core competitiveness lies in its platform-based technology system, effectively overcoming the core bottleneck of "engineering transformation" in biological manufacturing [1] - The company has successfully achieved seamless scaling from "gram-level research" to "thousand-ton-level production" through its complete technology path and eight innovative technology platforms [1] Industry Positioning - Yikole is set to be the first in China to achieve market approval for high-value functional raw materials such as human milk oligosaccharides (HMOs), steviol glycosides, and nest acid from 2023 to 2025, gaining a first-mover advantage [2] - The company has established over 20 mature product lines in the fields of biomedicine, green agriculture, and life health [2] - Yikole has formed joint ventures with industry leaders, such as "Hongmo Bio" with Mengniu Group for HMOs commercialization and "Yikotang" with Jinhwa Industrial for health sweetener operations [2] Strategic Collaboration - Guotou Juli's investment aligns with the national strategy to accelerate the development of biological manufacturing and create new productive forces [3] - The collaboration will focus on innovative platform construction and cutting-edge technology application research [3] - Both parties will prioritize advancing biosynthesis technology using carbon compounds like carbon dioxide, carbon monoxide, and methanol, supporting the sustainable development strategy of "not competing with food for land or grain" [3]

Core Viewpoint - The article discusses the advancements in synthetic biology, particularly focusing on optimizing yeast metabolism for carbon conservation and fixation, which is crucial for reducing CO2 emissions and achieving sustainable chemical production [3][4][5]. Summary by Sections 1. Introduction to Carbon Emissions and Synthetic Biology - The increasing use of fossil resources is leading to higher CO2 emissions, raising global concerns about climate change and the urgent need for alternative solutions to achieve carbon neutrality [4]. - Synthetic biology enables the use of inexpensive substrates, such as lignocellulose, for chemical production, thereby reducing reliance on fossil resources [4]. 2. Yeast as a Platform for Biomanufacturing - Yeast is highlighted as a robust microbial chassis for industrial biomanufacturing, capable of producing various compounds like terpenes and fatty acids [5]. - The complexity of yeast metabolism often results in unavoidable CO2 release during chemical synthesis, primarily through glycolysis, pentose phosphate pathway, and tricarboxylic acid cycle [5][6]. 3. Carbon Conservation Systems in Yeast - The article reviews recent advancements in constructing carbon conservation and fixation systems in yeast, focusing on avoiding unnecessary decarboxylation reactions to reduce carbon loss [6][8]. - Strategies include enhancing natural carboxylation reactions to promote carbon conservation, with specific examples of engineered yeast strains achieving significant improvements in product yields [8][11]. 4. Engineering Strategies and Results - Various engineering strategies are discussed, such as the non-oxidative glycolysis (NOG) pathway, which has been successfully implemented in yeast to improve carbon efficiency and product yields [10][11]. - Specific results include a 25% increase in β-farnesene yield and an 80% increase in β-carotene production through metabolic engineering [11][12]. 5. Future Directions in Low-Carbon Yeast Cell Factories - The future of biomanufacturing involves constructing low-carbon yeast cell factories that can recycle CO2 released during production and potentially utilize CO2 directly as a substrate for product synthesis [19][20]. - The article outlines the integration of carbon fixation pathways, such as the Calvin cycle and reductive glycine pathways, into yeast to enhance CO2 utilization [19][21]. 6. Conclusion - The advancements in synthetic biology and metabolic engineering present promising opportunities for developing sustainable biomanufacturing processes that significantly reduce carbon emissions and enhance product yields [3][4][5].

Core Viewpoint - The company, relying on an AI-driven synthetic biology technology platform, has developed several internationally competitive original technologies and established a rich product pipeline [1][2]. Group 1: Company Overview - Founded in 2015, the company has received over 400 million yuan in exclusive investment from Eli Lilly Asia Fund, making it one of the few synthetic biology enterprises with full-chain capabilities from R&D to production and commercialization [2]. - The company operates from its headquarters in Suzhou, with dual R&D centers in China and the U.S., and production bases in Hunan and Anhui, achieving an annual comprehensive production capacity exceeding 10,000 tons [3]. Group 2: Product and Market Development - The company has achieved stable supply and large-scale production of key raw materials, including the antibiotic raw material Florfenicol, pharmaceutical intermediates like NMN/NAD, and animal nutrition raw materials such as 25-hydroxyvitamin D3 [5]. - Its products are exported to over 20 countries globally, with a continuous increase in market share [1]. Group 3: Industry Events - The SynBioCon 2025 conference will be held from August 20-22 in Ningbo, focusing on AI-enabled biological manufacturing and featuring discussions on green chemicals, new materials, future food, and agriculture [8][9].

Core Viewpoint - Tianjin Hesheng Biotechnology Co., Ltd. has completed a multi-million Pre-A round financing, which will accelerate its technological innovation in the synthetic biology field and lead new trends in health and nutrition solutions [1][2]. Group 1: Company Overview - Established in August 2023, Hesheng Biotechnology is a key technology transfer enterprise of Nankai University, gathering a leading research team in synthetic biology with nearly 30 years of experience [2]. - The company has developed a "DBTL" (Design-Build-Test-Learn) technical platform, utilizing proprietary gene element databases and self-developed AI algorithms to create high-productivity microbial strains [2]. - Hesheng Biotechnology has a comprehensive technical coverage from product research and development to downstream applications, focusing on probiotics, functional foods, and medical foods [2]. Group 2: Key Product Focus - Human Milk Oligosaccharides (HMOs) - The core technology for Hesheng Biotechnology's HMO products originates from the National Key Basic Research Program (973 Program), with the team first synthesizing HMOs in 2016 and obtaining invention patents for industrial strains [3]. - The company has developed several industrial strain construction technologies for HMOs, including 2'-FL, 3-FL, and others, with a product purity of 98.98%, significantly exceeding domestic and international quality standards [3][4]. Group 3: Research and Application - Hesheng Biotechnology is committed to independent innovation and has initiated research on the functional applications of HMOs, including their role in immune balance and disease intervention [4].

Project Overview - The project is named "Annual Production of 855 Tons of Green Active Raw Materials" and is initiated by Shandong Yunluo Biotechnology Co., Ltd. [2] - The total estimated investment for the project is 100 million yuan, with 7.5% allocated for environmental protection, amounting to 7.5 million yuan [2]. - The construction period is planned for one year, and the project will utilize existing factory buildings while acquiring new production equipment [2]. Production Capacity - Upon reaching full production capacity, the project is expected to produce 1 ton of probiotics, 5 tons of ergothioneine, 126 tons of ectoine, 250 tons of hydroxypropyl tetrahydropyran triol (Bosein), and 473 tons of gluconic acid annually [2][3]. - The products will be sold externally and adhere to the company's quality standards [3]. Company Background - Shandong Yunluo Biotechnology Co., Ltd. is a wholly-owned subsidiary of Shanghai Yunluo Biotechnology Co., Ltd. [3]. - The company focuses on synthetic biology, specializing in enzyme gene mining, directed enzyme modification, cell factory construction, biological fermentation, and enzyme catalysis [3]. Industry Event - The Fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang [5]. - The conference will focus on the integration of AI and biological manufacturing, as well as the industrialization progress and opportunities in green chemistry, new materials, future food, and agriculture [5]. - Various stakeholders, including international enterprises, industry experts, and government representatives, will participate to explore trends in biological manufacturing and innovation [5].

Core Viewpoint - Synthetic biology is an underappreciated industry that has the potential to significantly change manufacturing methods, with Kasei Biotech positioned as a leading player in this field [1] Group 1: Technology Core - Kasei's core technology barriers include autonomous strain construction, industrial fermentation capabilities, and integrated engineering systems, allowing it to develop new materials without relying on external patents [4][5] - The company has successfully scaled fermentation processes from laboratory to industrial levels, achieving stable production rates essential for turning research into marketable products [4] - Kasei's integrated capabilities across the entire production chain enhance its ability to optimize yield and reduce costs [4][5] Group 2: Business Model - Kasei's business model focuses on selling products rather than licensing technology, with key products including bio-based pentamethylenediamine and long-chain dicarboxylic acids [5][6] - The company targets industrial material companies as primary customers, benefiting from strong customer loyalty and high switching costs [5] - Kasei's model emphasizes scalability and cost reduction, directly replacing fossil fuel-derived products [5][6] Group 3: Industry Positioning - Kasei is among the first companies globally to achieve large-scale production of bio-based materials, with a significant portion of its customer base in industrialized nations [6] - The company faces challenges such as long certification processes and policy barriers in international markets, indicating a slow but steady growth trajectory [6] Group 4: Financial Health - Kasei has maintained profitability for several years, with stable gross margins between 35-45%, indicating strong financial health relative to its industry [6][7] - The company invests 6-8% of its revenue in R&D annually, demonstrating a commitment to innovation while maintaining a healthy cash flow [7] - Kasei's net profit margin remains stable, reflecting a steady growth strategy rather than reliance on explosive revenue increases [6][7] Group 5: Moat and Long-term Evolution - Kasei's long-term advantages stem from a deepening technical system, strong customer relationships, and production capacity that cannot be easily replicated [7][8] - The company has established a "flywheel" effect through its technology, customer base, and supply chain, allowing for continuous product line expansion [7] - Kasei's strategy focuses on building a diversified product portfolio that supports long-term growth and stability [7][8] Group 6: Recent Performance - In Q1 2025, Kasei reported revenue of 776 million yuan, a year-on-year increase of 13.33%, indicating a recovery in demand for its core bio-based materials [8] - The net profit reached 137 million yuan, reflecting a 30.11% increase, showcasing improvements in profitability and cost management [8] - The company maintains a healthy cash flow without reliance on external financing, indicating robust financial management [8]

Core Insights - The Chinese biomanufacturing industry is projected to reach a scale of 1.01 trillion yuan in 2024, with a year-on-year growth of 15.4%. By 2030, the industry is expected to exceed 2.5 trillion yuan, with a compound annual growth rate of 16.8% [1]. Group 1: Industry Overview - The DT New Materials Research Institute has been actively monitoring and supporting the progress and innovation in the synthetic biology sector since the release of the "China Synthetic Biology Industry Map (2023)" which includes over 300 listed companies [1]. - The upcoming "4th Synthetic Biology and Green Biomanufacturing Conference (SynbioCon 2025)" will take place from August 20-22 in Ningbo, Zhejiang, where the "China Synthetic Biology Industry Distribution Map (2025 Edition)" will be announced, featuring over 500 representative biomanufacturing companies and their product information [1][9]. Group 2: Event Details - The conference will focus on five key areas: AI + Biomanufacturing, Green Chemistry and New Materials, Future Food, Future Agriculture, and Beauty Raw Materials, inviting industry leaders, experts, and various stakeholders to explore trends in biomanufacturing development during the 14th Five-Year Plan [9]. - Participants at the conference can receive a free copy of the industry map valued at 499 yuan, and eligible biomanufacturing companies can register to be included in the map [6][10].

Core Insights - The article highlights the rapid development and innovation in China's synthetic biology sector, particularly focusing on Shanghai as a leading hub for synthetic biology initiatives and projects [2][3][4]. Group 1: Industry Development - Shanghai is recognized as the primary force in China's synthetic biology development, with significant milestones such as the establishment of the Chinese Academy of Sciences' synthetic biology laboratory in 2008 [2]. - In 2023, Shanghai released an action plan to accelerate synthetic biology innovation and build a high-end biomanufacturing industry cluster from 2023 to 2025 [2]. - The Shanghai Municipal Science and Technology Commission has initiated key projects in synthetic biology and computational biology to support rapid industry growth [2]. Group 2: Funding and Support - Shanghai has allocated substantial funding for synthetic biology projects, including 42 million yuan for 18 projects and 37 million yuan for 16 projects [3]. - The city has established industrial clusters in areas like Zhangjiang Science City and Lingang New Area, providing comprehensive support from research and development to pilot testing [3]. Group 3: Notable Companies - A total of 66 representative companies from Shanghai have been listed in the "China Biomanufacturing 500+ Representative Enterprises List" based on their team, core products, and competitive potential [4]. - Key companies in the synthetic biology sector include Kasei Biotech, Enkasei Pharmaceutical, and Changjin Biotech, all of which are located in the aforementioned industrial parks [3][4]. Group 4: Upcoming Events - The Fourth Synthetic Biology and Green Biomanufacturing Conference will be held from August 20-22, 2025, in Ningbo, Zhejiang, focusing on AI and biomanufacturing, green chemicals, new materials, future food, and agriculture [19][21]. - The conference aims to gather international enterprises, industry experts, and government representatives to explore trends and innovations in the biomanufacturing sector [19].